1Y Annualised Return
▲2.51%
3Y Annualised Return
▲19.11%
5Y Annualised Return
▲34.36%
Sakar Healthcare Stock Performance
|
|
|
Sakar Healthcare Company background
Founded in: 2004
Managing director: Sanjay S Shah.
Sakar Healthcare Limited was incorporated as a Private Limited Company under the name Sakar Healthcare Private Limited on 26th March 2004. Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to Sakar Healthcare Limited. The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah.The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials Lyophilized Injections and Oral Solid Dossages. It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, antiemetics, antihistamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.The Company operates as contract development and manufacturing organisation (CDMO), being the EU GMP approved CMO for leading multinational pharmaceutical companies.Their 4 manufacturing facilities located at Changodar, Ahmedabad, Gujarat. have been approved by various international regulatory authorities and certified by ISO 9001:2008 (BVQI), WHOGMP, CGMP National Drug Authority, and it has obtained certain drug specific registrations from the relevant authorities in countries such as Uganda, Kenya, Yemen, Ethiopia, Congo, Ghana, Zimbabwe, Namibia, Nigeria, Cote divoire.In 2005, the Company started commercial production for Plant 1 which was established for production of Liquid Orals in 2007, it started exporting its products overseas started commercial production for Plant 2 which was established for production of Beta Lactum Tablet and Capsules and Dry Syrup Blactum. / Sachet in 2008. Further, it started commercial production for Plant 3 which was established for production of Liquid Injectibles (SVP) Ampoules and Liquid Injectibles (SVP) Vials.In 2012, it started commercial production for Plant 4 which was established for production of Dry Powder Injection. In 2017, it started Lyophilised injection product commercialisation.In 2020, the Company received EU GMP certification for SVP unit manufacturing liquid and Lyophilised injections. In 2021, the Oncology Unit started operations in Bavla location. In 202223, the Company started commercialization with Oncology product post receiving WHO GMP certification.
Sakar Healthcare Financial Highlights
Sakar Healthcare reported a Q1 FY 2025-26 revenue of ₹52.74 crore, up 14.3% YoY, with net profit increased 50.0% to ₹4.67 crore. For the full year FY2025–2026, revenue reached ₹178.9 crore and profit touched at ₹17.5 crore. As of Jun '25, Sakar Healthcare’s market capitalisation stood at ₹696.03 crores. Shareholding as of Jun '25 shows promoters holding 52.9%, with FIIs at 13.4%, DIIs at 22.5%, and public at %.
As of 20 Aug, 2025, Sakar Healthcare share price is ₹320.5. The stock opened at ₹325.2 and had closed at ₹317.1 the previous day. During today’s trading session, Sakar Healthcare share price moved between ₹311.00 and ₹325.20, with an average price for the day of ₹318.10. Over the last 52 weeks, the stock has recorded a low of ₹210.10 and a high of ₹380.80. In terms of performance, Sakar Healthcare share price has increased by 40.5% over the past six months and has increased by 2.51% over the last year.
Sakar Healthcare SIP Return Calculator
Over the past
1 year
3 years
5 years
Total Investment of ₹65,00,000
Would have become ₹65,82,575 (+1.27%)
Daily SIP of ₹25,000 would have become ₹65,82,575 in 1 year with a gain of ₹82,575 (+1.27%)
Sakar Healthcare Fundamental
Market Cap (in crs)
696.03
Face Value
10
Turnover (in lacs)
12.20
Key Metrics
Qtr Change %
52.55% Gain from 52W Low
3.3
Dividend yield 1yr %
0
Sakar Healthcare Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Sakar Healthcare Quarterly Revenue
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
52.74 Cr | 50.24 Cr | 43.42 Cr | 42.78 Cr | 41.15 Cr |
Sakar Healthcare Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
178.9 Cr | 156.53 Cr | 138.03 Cr | 130.4 Cr | 95.91 Cr | 85 Cr |
Sakar Healthcare Quarterly Net Profit/Loss
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|
4.67 Cr | 5.76 Cr | 4.53 Cr | 4.8 Cr | 2.41 Cr |
Sakar Healthcare Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
17.5 Cr | 11.67 Cr | 12.76 Cr | 15.18 Cr | 10.68 Cr | 9.62 Cr |
Sakar Healthcare Result Highlights
Result Summary
-
Sakar Healthcare Ltd reported a 21.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 27.7%.
-
Its expenses for the quarter were up by 22.3% QoQ and 29.3% YoY.
-
The net profit increased 49.7% QoQ and increased 93.8% YoY.
-
The earnings per share (EPS) of Sakar Healthcare Ltd stood at 2.1 during Q1 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Sakar Healthcare Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
320.50
Current Price
5Day EMA
323.60
10Day EMA
328.80
12Day EMA
330.60
20Day EMA
335.60
26Day EMA
337.40
50Day EMA
335.40
100Day EMA
322.80
200Day EMA
313.60
5Day SMA
324.90
10Day SMA
328.70
20Day SMA
341.40
30Day SMA
344.20
50Day SMA
344.10
100Day SMA
314.90
150Day SMA
297.40
200Day SMA
299.40
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 9382 Rs | 9382 Rs |
Week Rs | 8267 Rs | 8267 Rs |
Month Rs | 10049 Rs | 10049 Rs |
Resistance & Support
320.83
Pivot
Resistance
First Resistance
326.17
Second Resistance
335.23
Third Resistance
340.57
Support
First Support
311.77
Second support
306.43
Third Support
297.37
Relative Strength Index
32.28
Money Flow Index
12.57
MACD
-6.78
MACD Signal
-3.97
Average True Range
13.47
Average Directional Index
23.33
Rate of Change (21)
-10.27
Rate of Change (125)
35.86
Sakar Healthcare Peer comparison
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
100.05 | 100.06 | - | - | - | - | - | - | - | - | - | - | - | - | |
408.65 | 400.50 | - | - | - | - | - | - | - | - | - | - | - | - | |
484.00 | 478.00 | - | - | - | - | - | - | - | - | - | - | - | - | |
490.65 | 495.00 | - | - | - | - | - | - | - | - | - | - | - | - | |
1,062.30 | - | - | - | - | - | - | - | - | - | - | - | - | ||
Accent Microcell Ltd. | 303.00 | 303.00 | - | - | - | - | - | - | - | - | - | - | - | - |
Sakar Healthcare Share Price FAQs
How has Sakar Healthcare shares performed in the past ?
Sakar Healthcare share price in the past 1-year return was 1.63. The Sakar Healthcare share hit a 1-year low of Rs. 210.1 and a 1-year high of Rs. 380.8.
What is the market cap of Sakar Healthcare ?
The market cap of Sakar Healthcare is Rs. 696.03 Cr. as of 20/8/2025.
What is the current P/E ratio of Sakar Healthcare ?
The PE ratios of Sakar Healthcare is 35.15 as of 20/8/2025.
What is the current PB ratio of Sakar Healthcare ?
The PB ratios of Sakar Healthcare is 2.43 as of 20/8/2025
How to buy Sakar Healthcare shares?
You can easily buy Sakar Healthcare shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Sakar Healthcare ?
The 52-week high and low of Sakar Healthcare share price is ₹380.8 and ₹210.1 as of 20/8/2025.
What is the EPS of Sakar Healthcare ?
The earnings per share (EPS) of Sakar Healthcare stood at 2.1 during Q1 FY 2025-26.
Please be aware that Sakar Healthcare stock prices are subject to continuous fluctuations due to various factors.
Open Demat Account